Profound Medical
Profound Medical develops advanced, incision-free therapies using real-time MRI and thermal ultrasound for tissue ablation, offering technologies like TULSA-PRO® and Sonalleve®.
Services
Profound Medical develops customizable, incision-free therapies that combine real-time Magnetic Resonance imaging, thermal ultrasound, and closed-loop temperature feedback control. The company's offerings include technologies that allow for radiation-free ablation of tissue, actively preserving vital functionalities in patients.
Products
Profound Medical offers two main therapeutic technologies: TULSA-PRO® and Sonalleve®. TULSA-PRO® is designed for the customizable and predictable radiation-free ablation of prostate tissue, protecting the urethra and rectum to aid in maintaining the patient's natural abilities. Sonalleve® is utilized for the treatment of uterine fibroids and the palliative pain treatment of bone metastases. It has received approval from the China Food and Drug Administration for the non-invasive treatment of uterine fibroids.
Strategic Partnerships
Profound Medical has entered into strategic agreements to enhance its offerings and market reach. In February 2016, the company partnered with Siemens to expand collaboration efforts. Furthermore, in June 2017, Profound Medical acquired the Sonalleve MR-HIFU business from Philips, bolstering its portfolio of advanced therapeutic solutions.
Regulatory Approvals
TULSA-PRO®, one of Profound Medical's key technologies, received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in August 2019. This approval marks a significant milestone in the company's ability to offer innovative, non-invasive treatment options for prostate tissue ablation in the United States.
Headquarters
Profound Medical is headquartered at 2400 Skymark Avenue, Unit #6, Mississauga, ON L4W 5K5, Canada. The company's strategic location supports its operations and collaborations with key industry partners.